NCT00145158 2022-10-10
Immunization With 8 Peptides Mixed With CpG 7909 or Montanide ISA51 in Patients With Metastatic Cutaneous Melanoma
Ludwig Institute for Cancer Research
Phase 1/2 Terminated
Clinical Trials
8 trialsNCT00145145 2022-10-07
Immunization With the MAGE-3.A1 Peptide Mixed With the Adjuvant CpG 7909 in Patients With Metastatic Melanoma
Ludwig Institute for Cancer Research
Phase 1/2 Terminated
NCT00226993 2016-12-01
Phase I/II Study of Intratumoral Injection of CPG 7909, a TLR9 Agonist, Combined With Local Radiation for Patients With Recurrent Mycosis Fungoides.
Stanford University
Phase 1/2 Withdrawn
NCT00438880 2016-02-04
Agatolimod Sodium, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Recurrent or Refractory Non-Hodgkin Lymphoma
Mayo Clinic
Phase 1/2 Completed
NCT00031278 2011-05-30
Safety And Efficacy Study Of The Combination Of CpG 7909 And Herceptin In Patients With Metastatic Breast Cancer
Pfizer
Phase 1/2 Completed
NCT00669292 2010-09-09
Phaseâ… /â…¡ Study of URLC10-177 and TTK-567 Peptide Vaccine Combined With CpG7909 in Patients With Esophageal Cancer
Wakayama Medical University
Phase 1/2 Unknown
NCT00043407 2009-02-12
CPG 7909 in Patients Wih Stage IV Renal Cell Cancer
Pfizer
Phase 1/2 Completed
NCT00043420 2009-02-12
CPG 7909 in Patients With Cutaneous T-Cell Lymphoma
Pfizer
Phase 1/2 Completed